Aptevo Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Aptevo Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Aptevo Therapeutics Inc Strategy Report
- Understand Aptevo Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company that develops and commercializes oncology and hematology therapeutics. Its pipeline products include APVO436 for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); ALG.APV-527 for potential treatment of a broad spectrum of cancers including mesothelioma, cervical, prostate, renal, breast, non-small-cell-lung, gastric, colorectal and bladder cancers; APVO603 for solid tumors. Aptevo has received Orphan Drug Designation (ODD) for its pipeline product APVO436 from the US FDA for the treatment of acute myelogenous leukemia (AML). The pipeline immuno-oncology candidates are built on its proprietary Adaptir and Adaptir-Flex platform technologies. Aptevo is headquartered in Seattle, Washington, the US.
Headquarters
United States of America
Address
2401 4th Ave Ste 1050, Seattle, Washington, 98121-3460
Website
aptevotherapeutics.com
Telephone
1 206 8380500
No of Employees
40
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
APVO (NASD)
EPS
XYZ
Net Income (2022)
XYZ
-316.9%
(2022 vs 2021)
Market Cap*
$2.8M
Net Profit Margin (2021)
XYZ
211.3%
(2022 vs 2021)
* As of and is in US$
Aptevo Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Technology: |
| APVO436 for Myelodysplastic Syndrome (MDS) | Adaptir |
| APVO436 for Acute Myeloid Leukemia (AML) | Adaptir-Flex |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Aptevo Therapeutics Inc | AbbVie Inc | Bayer AG | Bristol-Myers Squibb Co | Amgen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | United States of America | United States of America |
| City | Seattle | North Chicago | Leverkusen | Princeton | Thousand Oaks |
| State/Province | Washington | Illinois | Nordrhein-Westfalen | New Jersey | California |
| No. of Employees | 40 | 50,000 | 99,723 | 34,100 | 26,700 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John E. Niederhuber, M.D. | Chairman | Executive Board | 2022 | 84 |
| Marvin L. White | President; Director; Chief Executive Officer | Executive Board | 2016 | 61 |
| Daphne Taylor | Senior Vice President; Chief Financial Officer | Senior Management | 2023 | 57 |
| Jeffrey G. Lamothe | Executive Vice President; Chief Operating Officer | Senior Management | 2023 | 57 |
| Scott C. Stromatt, MD | Senior Vice President - Clinical Development and Medical Affairs; Chief Medical Officer | Senior Management | 2016 | 63 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer